drugset / Trial / NCT07543276

Pharmacokinetic (PK) Evaluation of Nalmefene Formulations

NCT07543276

Phase 1 Completed 13 enrolled Knoa Pharma LLC Purdue Pharma LP · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.

Timeline

Start
2026-02-06
Primary completion
2026-04-03
Completion
2026-04-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nalmefene Small molecule 0.5 mg Intravenous